Peter H. O'Donnell to Capecitabine
This is a "connection" page, showing publications Peter H. O'Donnell has written about Capecitabine.
Connection Strength
1.180
-
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
Score: 0.689
-
Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma. Clin Genitourin Cancer. 2019 Feb; 17(1):e12-e18.
Score: 0.155
-
Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients. Oncotarget. 2016 Jun 21; 7(25):38359-38366.
Score: 0.132
-
Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer. 2012 Aug 15; 118(16):4063-73.
Score: 0.097
-
Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 04; 22(2):476-482.e1.
Score: 0.056
-
DPYD Testing: Time to Put Patient Safety First. J Clin Oncol. 2023 05 20; 41(15):2701-2705.
Score: 0.052